Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Qingdai Capsules (Fufang Qingdai Jiaonang) is a Traditional Chinese Medicine (TCM) formulation widely utilized in China for the treatment of moderate-to-severe plaque psoriasis. The primary active component is Qingdai (Indigo Naturalis), which contains the bis-indole alkaloids indigo and indirubin. These compounds exert therapeutic effects by acting as agonists for the aryl hydrocarbon receptor (AhR) and inhibitors of cyclin-dependent kinases (CDKs), which collectively work to normalize keratinocyte differentiation, inhibit excessive skin cell proliferation, and modulate the production of pro-inflammatory cytokines such as IL-17 and TNF-alpha. The formulation typically includes auxiliary herbs such as Salvia miltiorrhiza and Smilax glabra to improve microcirculation and clear heat-toxins. Clinical studies, including randomized controlled trials, have evaluated its efficacy in improving Psoriasis Area and Severity Index (PASI) scores and patient quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Qingdai Capsules.